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during 1996. Six therapeutic categories were analyzed.
Statistical analyses utilizing multiple regression and anal-
ysis of covariance were performed. 
RESULTS: Significant associations (p  0.001) were
found between plan characteristics and cost of pharma-
ceuticals. Utilization differed (p  0.0001) among vari-
ous plan characteristics such as co-payment, mode of
payment, formulary status and pharmacy type after con-
trolling for average wholesale price and days supply. 
CONCLUSIONS: Results obtained in this study may be
helpful in understanding some of the factors associated
with cost of pharmaceuticals. For example, the inverse
relationship of pharmaceutical cost with eligible days
may be helpful in budgeting program costs while the
non-significant association of pharmaceutical cost with
number of members eligible suggests a lack of importance
of group size in negotiating pharmacy benefit contracts.
Differences in utilization among various co-payment levels
suggest the effectiveness of different co-payment levels in
promoting use of generic products. Lower utilization found
under capitation may be encouraging to those PBMs ac-
cepting a capitation method of reimbursement. Associa-
tion of closed formularies with higher utilization indicates
the importance of adjusting cost data for rebates before
evaluating formulary strategies. Finally, differences in utili-
zation between independent and chain pharmacies suggest
the importance of careful provider contract negotiation.
OUTCOMES (QUALITY OF LIFE) RESEARCH 
METHODS ISSUES
POR1
METHODOLOGY FOR DEVELOPING AN INDEX 
SCORE FOR BOTHERSOMENESS OF ADVERSE 
EVENTS
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Measures of adverse effect frequency and severity do not
accurately depict patients’ tolerance to an illness and/or a
treatment. The adverse effect frequency model is also a
weak predictor for tolerability and compliance. Additional
multidimensional variables are required to fully assess the
impact on quality of life which can be used as explanatory
variables to develop an index for bothersomeness to pre-
dict tolerability and hence compliance to therapy. 
OBJECTIVE: To develop a methodology for developing
an index of bothersomeness. 
METHODS: Data on bothersomeness were collected on
50 patients participating in a randomized, placebo-con-
trolled clinical trial. At baseline and final visits, patients
completed a questionnaire designed to capture the fre-
quency and bothersomeness of the impact of illness on
seven domains of quality of life. Regression methods
were used to test the response to bothersome scale for lin-
earity. Additive and predictive models were used to convert
the scale to a domain summary scores and hence a compos-
ite index for patient bothersomeness. Finally, multivariate
models (stepwise procedure) were used with clinical and
demographic variables as predictor and composite index
derived from additive and predictive methods as dependent
variables to estimate observed variance and model fit. 
RESULTS: An index scores for bothersomeness was esti-
mated using the additive and predictive methods using
data collected over time on 50 patients participating in a
clinical trial with the best model fit. 
CONCLUSION: The methodology used to calculate the
bothersome index can be used in other disease and treat-
ment modalities. The index scores may be used to better
describe patients’ tolerance, therefore improving the com-
munication between patient and physician when discussing
the treatment or illness impact on patients’ quality of life.
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PSYCHOMETRIC EVALUATION OF 
THE PATIENT MEDICATION 
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Jordan J, Tolson J, Jhingran P, Demasi R, Pham S, Capuano G
Glaxo Wellcome Inc., Research Triangle Park, NC, USA
OBJECTIVE: The purpose of this study was to conduct a
psychometric evaluation of the Patient Medication Ad-
herence Questionnaire (PMAQ), an HIV-specific instru-
ment designed to assess medication-taking behavior as
well as barriers and motivators affecting adherence. 
METHODS: The PMAQ was prospectively administered
to 410 patients in three studies: 1) a focus group of HIV
infected patients (n  67); 2) a cross-sectional observa-
tional cohort study (n  120); and 3) a clinical trail, with
evaluations at baseline, and weeks 8 and 16 (n  223).
The Multitrait/Multi-item Analysis Program-Revised was
used to evaluate reliability and validity for each of the five
hypothesized PMAQ dimensions: Remembering (REM),
Scheduling and Timing (SCH), Physical Effects (PE),
Knowledge and Attitudes (KNO), and Social Support (SS). 
RESULTS: Results consistent across the studies and
across multiple visits within the clinical trial are reported.
Cronbach’s alpha for four dimensions ranged between
0.43 to 0.73 and between 0.76 to 0.79 for the total score.
For the same dimensions, discriminant validity was suffi-
cient to suggest multitrait scaling even though a few
items within the dimensions produced weak (0.40)
item-scale correlations. To assess evidence of convergent
validity, the same dimensions had scale-scale correlations
0.42. The dimension that did not perform well across
these studies was KNO. Given its importance in earlier
research, this finding most probably reflects the heteroge-
neous nature of the items within this dimension. The cor-
relations between REM, SCH, and PE with missed doses
were moderate. SS was unrelated to missed doses. 
CONCLUSION: Even though the KNO dimension war-
rants further evaluation, the PMAQ generally demon-
strates adequate psychometric properties. It can be used
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to assess barriers and motivators to adherence in research
settings, and may be predictive of adherence.
POR3
EDMONTON QUALITY ASSESSMENT TOOL FOR 
DRUG UTILIZATION REVIEWS (EQATDUR):
AN INSTRUMENT FOR ASSESSING THE 
METHODOLOGIC RIGOR OF DRUG 
UTILIZATION REVIEWS
Spooner CH, Pickard AS, Menon D, Assiff L
Institute of Pharmaco-Economics, Edmonton, AB, Canada
OBJECTIVE: The purpose of this project was: 1) to de-
velop an instrument that would provide a systematic ap-
proach to evaluating the methodological rigor of published
drug utilization reviews (DURs) and DUR programs; and
2) to determine the inter-rater reliability of the instrument’s
adequacy to discriminate between high and low quality
studies. 
METHODS: Based upon guidelines that have been ac-
cepted for appraising controlled clinical trials and before
and after studies, a multidisciplinary panel identified ar-
eas where bias could be introduced in the design and con-
duct of DURs. These areas included selection bias in the
sample selection; detection bias in the data collection; se-
lection, detection and exclusion bias if an intervention
occurred; and observer bias in the data analysis. Items
constituting the criteria to be met were generated for
each section. The item content, instructions and scoring
system of the EQATDUR were reviewed and revised by
clinical and methodological experts. The instrument was
piloted and re-tested for inter-rater reliability among rat-
ers from four relevant backgrounds using twenty pub-
lished community and hospital based DUR studies evalu-
ating antibiotic use. 
RESULTS: The present version of the EQATDUR in-
cludes five sections, each containing two to four criteria
to detect the presence of relevant systematic bias. The in-
strument produced strong inter-rater agreement as repre-
sented by an intra class correlation coefficient of 0.76
calculated from the aggregate score for each article. 
CONCLUSION: The EQATDUR has the potential to be
a useful tool that can assist researchers to determine the
strength of the methodological quality of DUR studies.
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Quality of life (QoL) assessment has become a vital part
of international clinical trials. This has made it necessary
to produce cross-culturally valid instruments to make
comparisons of health status outcomes and pool data
across countries. The SLICE/LIFE questionnaire is a 11-
item instrument developed in US English to measure the
impact of psychological disorders on patients’ lives. Prior
to use in an international trial including patients with bi-
polar disorders, the original questionnaire underwent lin-
guistic validation in 16 languages. 
METHODS: This process involved the recruitment of a
QoL specialist in each country. Two forward translations
were produced by two native target language speakers,
fluent in English. These were reconciled and back-trans-
lated into English. The clarity and appropriateness of the
wording were tested in a sample target population, com-
pared and internationally harmonized. The developers
clarified concepts underlying problematic items. 
RESULTS: This process gave rise to linguistic and cul-
tural issues. These included finding a suitable equivalent
for the notion of “impairment” for which different syn-
tactic structures were adopted in most translations. Fur-
thermore, it was impossible to maintain a literal transla-
tion of the term “partner” in conjunction with “someone
you live with” as the interpretation of the two concepts
differed across countries. Finally, as in most cultures it
would have sounded insulting to employ a literal transla-
tion of “mental illness” in the context of a questionnaire,
more adapted expressions needed to be found. 
CONCLUSION: A rigorous methodology ensured con-
ceptual equivalence and acceptability of the translations.
Psychometric testing will be conducted to ensure reliability
and validity of each translation, appropriateness of the
questionnaire in each country, and comparability of data
across countries.
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OBJECTIVE: The purpose of this study was to determine
the applicability of a multiple criteria decision technique to
the evaluation of new drug agents for formulary placement
in managed care settings. The Analytic Hierarchy Process
(AHP), developed by Dr. Thomas Saaty in 1977, which
utilizes pair-wise comparisons among all feasible alterna-
tive agents within a hierarchical breakdown of the organi-
zation’s decision-making preference structure, was utilized
to determine the best choice for formulary inclusion. 
METHODS: The analytical hierarchy process was used
to screen three drug agents used in the treatment of rheu-
matoid arthritis. This methodology employs a stepwise
procedure: 1) Identify alternative drug agents being con-
sidered for formulary inclusion; 2) Define organizational
preference structure (decision criteria); 3) Quantify the
preference of each agent relative to every other agent be-
